The versatility of oligonucleotides as potential therapeutics

Bibliography

• OPALINSKA JB: Nucleic acid drugs in the clinic. Expert Opin. Drug Discov. (2007) 2(3):321-333.
   Google Scholar
• ECKSTEIN F: Phosphorothioate oligonucleotides: what is the origin and what is unique about them? Antisense Nucleic Acid Drug Dev. (2000) 10:117-121.
   PubMedGoogle Scholar
• MONIA BP, LESNIK EA, GONZALES C et al.: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. (1993) 268:14514-14522.
   PubMed Web of Science ®Google Scholar
• FLUITER K, FRIEDEN M, VREIJLING J et al.: On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem (2005) 6:1104-1109.
   PubMed Web of Science ®Google Scholar
• KALOTA A, KARABON L, SWIDER CR et al.: 2′-Deoxy-2′-fluoro-β-D- arabinonucleic acid (2′F-ANA) modified oligonucleotides effect highly efficient, and persistent gene silencing. Nucleic Acids Res. (2006) 34:451-461.
   PubMed Web of Science ®Google Scholar
• KOIZUMI M, TAKAGI-SATO M, OKUYAMA R et al.: Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2′-O-(2-methoxy)ethyl-modified oligonucleotides. Oligonucleotides (2006) 16:253-262.
   PubMed Web of Science ®Google Scholar
• OPALINSKA JB, KALOTA A, GIFFORD LK et al.: Oxetane modified, conformationally constrained, antisense oligodeoxynucleotides function efficiently as gene silencing molecules. Nucleic Acids Res. (2004) 32:5791-5799.
   PubMed Web of Science ®Google Scholar
• FISHER F, ABRAMOV M, VAN AERSCHOT A, XU D, JULIANO RL, HERDEWIJN P: Inhibition of MDR1 expression with altritol modified siRNAs. Nucleic Acids Res. (2007) 35:1064-1074.
   PubMed Web of Science ®Google Scholar
• HALL AHS, WAN J, SPESOCK A, SERGUEEVA Z, SHAW BR, ALEXANDER KA: High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res. (2006) 34:2773-2781.
   PubMed Web of Science ®Google Scholar
• ZAMECNIK PC, STEPHENSON ML: Inhibition of Rouse sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA (1978) 75:280-284.
   PubMed Web of Science ®Google Scholar
• DECLERCQ E, ECKSTEIN F, MERIGAN TC: Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science (1969) 165:1137-1139.
   PubMed Web of Science ®Google Scholar
• MATSUKURA M, SHINOZUKA K, ZON G et al.: Phosphorothioate analogs of oligodeoxyribonucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA (1987) 84:7706-7710.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, GOODCHILD J, CIVEIRA MP, THORNTON AH, SARIN PS, ZAMECNIK PC: Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA (1988) 85:7079-7083.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, MAYRAND SH, ZAMECNIK PC, PEDERSON T: Site-specific excision from RNA by RNase H and mixed phosphate-backbone oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA (1990) 87:1401-1405.
   PubMed Web of Science ®Google Scholar
• FURDON PJ, DOMINSKI Z, KOLE R: RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodieseter bonds. Nucleic Acids Res. (1989) 17:9193-9204.
   PubMed Web of Science ®Google Scholar
• WATANABE TA, RICHARDS RS, LEVIN AA: Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides (2006) 16:169-180.
   PubMed Web of Science ®Google Scholar
• SUMMERTON J: Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta (1999) 1489:141-158.
   PubMed Web of Science ®Google Scholar
• DEVI GR, BEER TM, COLRLESS CL, ARORA V, WELLER DL, IVERSEN PL: In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. (2005) 11:3930-3938.
   PubMed Web of Science ®Google Scholar
• HEIDENREICH O, GRYAZNOV S, NERENBERG M: RNase H-independent antisense activity of oligonucleotide N3′-P5′ phosphoramidates. Nucleic Acids Res. (1997) 25:776-780.
   PubMed Web of Science ®Google Scholar
• ROBERTS J, PALMA E, SAZANI P, ORUM H, CHO M, KOLE R et al.: Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol. Ther. (2006) 14:471-475.
   PubMed Web of Science ®Google Scholar
• ALTER J, LOU F, RABINOWITZ A et al.: Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. (2006) 12:175-176.
   PubMed Web of Science ®Google Scholar
• MCCLOREY GM, MOULTON HM, IVERSENPL, FLETCHER S, WILTON SD: Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. (2006) 13:1373-1381.
   PubMed Web of Science ®Google Scholar
• HOCHREITER AE, XIAO H, GOLDBLATT EM et al.: Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis. Clin. Cancer Res. (2006) 15:3184-3192.
   Google Scholar
• KRIEG A: Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. (2006) 5:471-484.
   PubMed Web of Science ®Google Scholar
• FILIPOWICZ W, JASKIEWICZ L, KOLB FA, PILLAI RS: Posttransriptional gene silencing by siRNAs and miRNAs. Curr. Opin. Struct. Biol. (2005) 15:1-11.
   Web of Science ®Google Scholar
• TOMARI Y, ZAMORE PD: Perspective: machines for RNAi. Genes Devel. (2005) 19:517-529.
   PubMed Web of Science ®Google Scholar
• VALENCIA-CANCHEZ MA, LIU J, HANNON GJ, PARKER R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Devel. (2006) 20:515-524.
   PubMed Web of Science ®Google Scholar
• SONTHEIMER EJ: Assembly and functionof RNA silencing complexes. Nat. Rev. Mol. Cell Biol. (2005) 6:127-138.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, HARBORTH J, LENDECKEL W, YALCIN A, WEBER K, TUSCHLT: Duplexes of 21-nucleotides RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494-498.
   PubMed Web of Science ®Google Scholar
• MANOHARAN M: RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. (2004) 8:570-579.
   PubMed Web of Science ®Google Scholar
• ELMEN J, THONBERG H, LJUNGBERG K et al.: Locked nucleic acids (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. (2005) 33:439-447.
   PubMed Web of Science ®Google Scholar
• DOWLER T, BERGERON D, TEDESCHI AL, PAQUET L, FERRARI N, DAMHA MJ: Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-β-D-arabinonucleic acid (FANA). Nucleic Acids Res. (2006) 34:1669-1675.
   PubMed Web of Science ®Google Scholar
• BEHLKE, MA: Progress towards in vivo use of siRNAs. Mol. Ther. (2006) 13:644-670.
   PubMed Web of Science ®Google Scholar
• DYKXHORN DM, PALLISER D, LIEBERMAN J: The silent treatment: siRNAs as small molecule drugs. Gene Ther. (2006) 13:541-552.
   PubMed Web of Science ®Google Scholar
• BUMCROT D, MANOHARAN M, KOTLIANSKY V, SAH DWY: RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. (2006) 12:711-719.
   Google Scholar
• KIM DH, ROSSI JJ: Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. (2007) 8:173-184.
   PubMed Web of Science ®Google Scholar
• DE FOUGEROLLES A, VORNLOCHER H-P, MARAGANORE J, LIEBERMAN J: Interfering with Disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. (2007) 6:443-453.
   PubMed Web of Science ®Google Scholar
• SOUTSCHEK J, AKINC A, BRAMLAGE B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432:173-178.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN TS, LEE ACH, AKINC A et al.: RNAi-mediated gene silencing in non-human primates. Nature (2006) 441:111-114.
   PubMed Web of Science ®Google Scholar
• SANTEL A, ALEKU M, KEIL O et al.: RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene. Ther. (2006) 13:1360-1370.
   PubMed Web of Science ®Google Scholar
• SONG E, ZHU P, LEE SK et al.: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. (2005) 23:709-717.
   PubMed Web of Science ®Google Scholar
• WILSON A, ZHOU W, CHAMPION HC et al.: Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol. Ther. (2005) 12:510-518.
   PubMed Web of Science ®Google Scholar
• TAKESHIDA F, MINAKUCHI Y, NAGAHARA S et al.: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. USA (2005) 102:12177-12182.
   PubMed Web of Science ®Google Scholar
• SHEN J, SAMULI R, AKIYAMA H et al.: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene. Ther. (2006) 13:225-234.
   PubMed Web of Science ®Google Scholar
• THAKKER DR, NATT F, HÜSKEN D et al.: Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Natl. Acad. Sci. USA (2004) 101:17270-17275.
   PubMed Web of Science ®Google Scholar
• BITKO V, MUSIYENKO A, SHULYAYEVA O, BARIK S: Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. (2005) 11:50-55.
   PubMed Web of Science ®Google Scholar
• LI B-J, TANG Q, CHENG D et al.: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. Nat. Med. (2005) 11:944-951.
   PubMed Web of Science ®Google Scholar
• KUMAR P, LEE SK, SHANKAR P, MANJUNATH N: A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PloS Med. (2006) 3:e96.
   PubMed Web of Science ®Google Scholar
• MORRISSEY DV, LOCKRIDGE JA, SHAW L et al.: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. (2005) 23:1002-1007.
   PubMed Web of Science ®Google Scholar
• PALLISER D, CHOWDHURY D, WANG Q-Y et al.: A siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2006) 439:89-94.
   PubMed Web of Science ®Google Scholar
• TOMPKINS SM, LO C-Y, TUMPEY TM, EPSTEIN SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA (2004) 101:8682-8686.
   PubMed Web of Science ®Google Scholar
• LIN X, RUAN X, ANDERSON MG et al.: siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. (2005) 33:4527-4535.
   PubMed Web of Science ®Google Scholar
• JACKSON AL, BURCHARD J, SCHELTER J et al.: Widespread siRNA ‘off-target’ transcript silencing mediated by seed region sequence complementarity. RNA (2006) 12:1179-1187.
   PubMed Web of Science ®Google Scholar
• JACKSON A, BURCHARD J, LEAKE D et al.: Position-specific chemical modification of siRNAs reduces ‘off-target’ transcript silencing. RNA (2006) 12:1197-1205.
   PubMed Web of Science ®Google Scholar
• PEI Y, TUCHL T: On the art of identifying effective and specific siRNAs. Nat. Methods (2006) 9:670-676.
   Google Scholar
• HORNUNG V, GUENTHNER-BILLER M, BOURQUIN C et al.: Sequence-specific potent induction of IFN-α by a short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. (2005) 11:263-270.
   Google Scholar
• HEIDEL JD, HU S, LIU XF, TRIHE TJ, DAVIS ME: Lack of interferon response in animals to naked siRNAs. Nat. Biotechnol. (2004) 22:1579-1582.
   PubMed Web of Science ®Google Scholar
• MARQUES JT, WILLIAMS BRG: Activation of mammalian immune systems by siRNAs. Nat. Biotechnol. (2005) 11:13991405.
   Google Scholar
• SCHLEE M, HORNUNG V, HARTMANN G: siRNA and isRNA: two edges of one sword. Mol. Ther. (2006) 14:463-470.
   Google Scholar
• HORNUNG V, ELLEGAS J, KIM S et al.: 5′-Triphosphate RNA is the ligand for RIG-I. Science (2006) 314:994-997.
   PubMed Web of Science ®Google Scholar
• MCNAMARA JO, ANDRECHEK ER, WANG Y et al.: Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. (2006) 24:1005-1015.
   PubMed Web of Science ®Google Scholar
• CHU TC, TWU KY, ELLINGTON A, LEVY M et al.: Aptamer mediated siRNA delivery. Nucleic Acids Res. (2006) 34:e73.
   PubMed Web of Science ®Google Scholar
• WEILER J, HUNZIGER J, HALL J: Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther. (2006) 13:496-502.
   PubMed Web of Science ®Google Scholar
• KRÜTZFELDT J, POY MN, STOFEL M: Strategies to determine the biological function of microRNAs. Nat. Genet. (2006) 38(Suppl.):S14-S19.
   PubMed Web of Science ®Google Scholar
• KRÜTZFELDT J, RAJEWSKY N, BRAICH R et al.: Silencing of microRNAs in vivo with ‘antagomirs’. Nature (2005) 438:685-689.
   PubMed Web of Science ®Google Scholar
• ESAU C, DAVIS S, MURRAY SF et al.: miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. (2006) 3:87-98.
   PubMed Web of Science ®Google Scholar
• DAVIS S, LOLLO B, FREIER S, ESAU C: Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. (2006) 34:2294-2304.
   PubMed Web of Science ®Google Scholar
• LILLEY DMJ: Structure, folding and mechanisms of ribozymes. Curr. Opin. Struct. Biol. (2005) 15:1-11.
   Web of Science ®Google Scholar
• NISSEN P, HANSEN J, BAN N, MOORE PB, STEITZ TA: The structural basis of ribosome activity in peptide bond synthesis. Science (2000) 289:920-930.
   PubMed Web of Science ®Google Scholar
• SALEHI-ASHTIANI K, LUPTAK A, LITOVCHICK A, SZOSTAK JW: A genomewide search for ribozymes reveals an HDV-like sequence I the human CPEB3 gene. Science (2006) 313:1788-1792.
   PubMed Web of Science ®Google Scholar
• WENG DE, MACI PA, RADKA SF et al.: A Phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther. (2005) 4:948-955.
   PubMed Web of Science ®Google Scholar
• BREAKER RR, JOYCE GF: A DNA enzyme that cleaves RNA. Chem. Biol. (1994) 1:223-229.
   PubMedGoogle Scholar
• ACHENBACH JC, CHIUMAN W, CRUZ RPG, LI Y: DNAzymes: from creation in vitro to application in vivo. Curr. Pharmaceut. Biotechnol. (2004) 5:321-336.
   PubMed Web of Science ®Google Scholar
• PATI SD, RHODES DG, BURGESS DJ: DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. (2005) 7:E61-E77.
   PubMed Web of Science ®Google Scholar
• SCHUBERT S, FÜRSTE JP, WERK D et al.: Gaining target access for deoxyribozymes. J. Mol. Biol. (2004) 339:355-363.
   PubMed Web of Science ®Google Scholar
• RIVORY L, TUCKER C, KING A et al.: The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity. Oligonucleotides (2006) 16:297-312.
   PubMed Web of Science ®Google Scholar
• FAHMY RG, WALDMAN A, ZHANG G et al.: Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nat. Biotechnol. (2006) 24:856-863.
   PubMed Web of Science ®Google Scholar
• TUERK C, GOLD L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 249:505-510.
   PubMed Web of Science ®Google Scholar
• BLANK M, BLIND M: Aptamers as tools for target validation. Curr. Opin. Chem. Biol. (2005) 9:336-342.
   PubMed Web of Science ®Google Scholar
• LEE JF, STOVALL GM, ELLINGTON AD: Aptamer therapeutics advance. Curr. Opin. Chem. Biol. (2006) 10:282-289.
   PubMed Web of Science ®Google Scholar
• QUE-GEWIRTH NS, SULLENGER BA: Gene therapy progress and prospects: RNA aptamers. Gene Ther. (2007) 14:283-291.
   PubMed Web of Science ®Google Scholar
• RUSCONI CP, SCARDINO E, LAYZER J. et al.: RNA aptamers as reversible antagonists of coagulation Factor IXa. Nature (2002) 419:90-94.
   PubMed Web of Science ®Google Scholar
• RUSCONI CP, ROBERTS JD, PITOC GA et al.: Antidote-mediated control of an anticoagulant aptamer in vivo. Nat. Biotechnol. (2004) 11:1423-1428.
   Google Scholar
• AURUP H, WILLIAMS DM, ECKSTEIN F: 2′-Fluoro- and 2′-amino-2′-deoxy 5′-triphosphates as substrates for T7 RNA polymerase. Biochemistry (1992) 31:9636-9641.
   PubMed Web of Science ®Google Scholar
• GRAGOUDAS ES, ADAMS AP, CUNNINGHAM ET et al.: Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. (2004) 351: 2805-2816.
   PubMed Web of Science ®Google Scholar
• LEE J-H, CANNY MD, DE ERKENEZ A, KRILLEKE D, NG Y-S, SHIMA DT: A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc. Natl. Acad. Sci. USA (2005) 102:18902-18907.
   PubMed Web of Science ®Google Scholar
• BURMEISTER PE, WANG C, KILLOUGH JR et al.: 2′-Deoxy purine, 2′-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. Oligonucleotides (2006) 16:337-351.
   PubMed Web of Science ®Google Scholar
• HUNAG J, MOORE J, SOFFER S et al.: Highly specific antiangeniogenic therapy is effective in suppressing growth of experimental Wilms tumors. J. Pediatr. Surg. (2001) 36:357-361.
   PubMed Web of Science ®Google Scholar
• KIM ES, SERUR A, HUANG J et al.: Potent VEGF blockade causes regression of coopted vesels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA (2002) 99:11399-11404.
   PubMed Web of Science ®Google Scholar
• HWANG B, HAN K, LEE S-W: Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer. FEBS Lett. (2003) 548:85-89.
   PubMed Web of Science ®Google Scholar
• DARFEUILLE F, ARZUMANOV A, GAIT M, DI PRIMO C, TOULMÉ J-J: 2′-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry (2002) 41:12186-12192.
   PubMed Web of Science ®Google Scholar
• DI PRIMO C, RUDLOFF I, REIGADAS S, ARZUMANOV AA, GAIT MJ, TOULMÉ J-J: Systematic screening of LNA/2′-O-methyl chimeric derivatives of a TAR RNA aptamer. FEBS Lett. (2007) 581:771-774.
   PubMed Web of Science ®Google Scholar
• HANNOUSH RN, CARRIERO S, MIN K-L, DAMHA MJ: Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells. Chembiochem (2004) 5:527-533.
   PubMed Web of Science ®Google Scholar
• PURSCHKE WG, EULBERG D, BUCHNER K, VONHOFF S, KLUSSMANN S: An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. Proc. Natl. Acad. Sci. USA (2006) 103:5173-5178.
   PubMed Web of Science ®Google Scholar
• MANN MJ: Transcription factor decoys, a new model for disease intervention. Ann. NY Acad. Sci. (2005) 1058:128-139.
   PubMed Web of Science ®Google Scholar
• QUARCOO D, WEIXLER S, GRONEBERG D et al.: Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. J. Allergy Clin. Immunol. (2004) 114:288-295.
   PubMed Web of Science ®Google Scholar
• DE VRY CG, PRASAD S, KOMUVES L et al.: ‘Non-viral’ delivery of NF-κB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut (2007) 56:524-533.
   PubMed Web of Science ®Google Scholar
• GIRVAN AC, TENG Y, CASSON LK et al.: AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming complex with NF-κB essential modulator (NEMO) and nucleolin. Mol. Cancer Ther. (2006) 5:1790-1799.
   PubMed Web of Science ®Google Scholar
• DEBART F, ABES S, DEGLANE G et al.: Chemical modifications to improve the cellular uptake of oligonucleotides. Curr. Top Med. Chem. (2007) 7:727-737.
   PubMed Web of Science ®Google Scholar